Johnson & Johnson Withdraws 300 Stents from Market
84305
Johnson & Johnson on Thursday said  it has voluntarily withdrawn 300 of its Cypher stents from the  U.S. market after determining that the coating on six of the  devices did not meet specifications.
758481
Drug maker Merck &amp; Co. Inc. (MRK) dominated trading in US stocks on Thursday, single-handedly driving the 30-stock Dow Jones average lower after it withdrew its arthritis
59069
NEW YORK - The stunning news Thursday that Merck &amp; Co. is withdrawing its pain reliever Vioxx from the market because of health risks is the latest in a series of blows to what only a few years ago was the
140168
Merck &amp; Co Inc. on Thursday pulled its arthritis drug Vioxx off the market because it increases the risk of heart attack and stroke, a move that sent the company&#39;s
539969
Meta-analysis finds J&J's stents are safer than Boston Scientific's stents -- maybe.
54306
Boston Scientific Corp. may forecast a drop in third-quarter sales of its Taxus heart stent after three recalls cut demand for the device, the company's top-selling product.
265306
Johnson &amp; Johnson will delay by five months the release of a study comparing its Cypher heart device with Boston Scientific Corp.'s Taxus, the first large-scale comparison of the only two drug-coated stents on the market.
500261
Johnson & Johnson's drug-coated stent slightly outperformed Boston Scientific's version in reopening arteries that had been clogged by lesions following the earlier insertion of bare-metal stents, a study said on Tuesday.
324653
Abbottâs stock price has fallen more than 7 percent since early October amid worries about whether the F.D.A. will speedily approve the companyâs Xience heart stent.
173143
Johnson &amp; Johnson's drug-coated Cypher heart stent may be better than Boston Scientific's Taxus for repeat procedures to unclog some arteries, according to a study in the Jan. 12 Journal of the American Medical Association.
550945
The catheter that triggered three safety recalls by Boston Scientific Corp. of its best-selling Taxus coronary stent after being linked to three deaths and 47 injuries had not been subjected to the rigors of a human clinical trial, FDA records show.
242397
Boston Scientific Corp. said yesterday it has won back the market share that its flagship cardiac stent system held before three safety recalls reduced doctors' orders of the product.
601534
In September, the widely used painkiller Vioxx was pulled from the market after studies indicated that it doubled the risk of heart attack and stroke.
90989
The medical device maker reported a third-quarter loss of $272 million on charges related to acquisitions and asset sales, as the companyâs top-selling stent continued to slump.
632359
Shares of Atherogenics Inc. opened down 7.2 percent on the Nasdaq Wednesday following a pre-market report that the drug developer is abandoning further clinical trials of its AGIX-4207 treatment for rheumatoid arthritis.
526354
Results of a study showing patients with acute heart attacks are more likely to die if given a drug-coated stent than a bare metal one are out of line with other findings, stent maker Johnson & Johnson said on Tuesday.
769273
Nov. 8, 2004 -- Stents cut a patient&#39;s risk of having a repeat balloon angioplasty to clear a clogged artery. But patients who get stents don&#39;t survive any longer than those who don&#39;t get them.